It is a definite long shot, but is it possible? Absolutely. If Kevetrin is a breakthrough success and becomes the next generation broad spectrum cancer treatment, Prurisol fires on all cylinders and helps ith psoriasis as well as other autoimmune diseases, a bidding war could go high enough that we could eclipse what happened with Pharmasset. This is just me having a little speculative fun and doing a keg stand with the kool aid, by no means do I think this is the most likely scenario.

My true belief is that the CEO will be patient enough to let both Prurisol and Kevetrin develop far enough in trials that a 12-15B valuation would be a very real possibility.